`Case 1:20-cv-00393-LO-TCB Document 721-4 Filed 06/16/21 Page 1 of 9 Page|D# 17750
`
`
`
`
`
`
`
`EXHIBIT 5
`
`
`EXHIBIT 5
`
`
`
`
`
`Case 1:20-cv-00393-LO-TCB Document 721-4 Filed 06/16/21 Page 2 of 9 PageID# 17751
`
`
`UNITED STATES DISTRICT COURT
`FOR THE EASTERN DISTRICT OF VIRGINIA
`Alexandria Division
`
`
`RAI STRATEGIC HOLDINGS, INC. and
`R.J. REYNOLDS VAPOR COMPANY,
`
`Plaintiffs and Counterclaim Defendants,
`
`
`
`
`
`
`
`v.
`
`Case No.: 1:20cv00393-LO-TCB
`
`ALTRIA CLIENT SERVICES LLC; PHILIP
`MORRIS USA, INC.; and PHILIP MORRIS
`PRODUCTS S.A.,
`
`
`
`Defendants and Counterclaim Plaintiffs.
`
`
`PLAINTIFF R.J. REYNOLDS VAPOR COMPANY’S THIRD NOTICE OF RULE
`30(B)(6) DEPOSITION TO DEFENDANT PHILIP MORRIS PRODUCTS S.A.
`
`Please take notice that Plaintiff R.J. Reynolds Vapor Company (“RJRV”), pursuant to
`
`Federal Rule of Civil Procedure 30(b)(6), will take the deposition of Defendant Philip Morris
`
`Products S.A. (“PMP”) through persons designated by PMP to testify on its behalf with respect to
`
`the topics listed in Schedule A hereto, at the offices of Jones Day, 51 Louisiana Ave., N.W.,
`
`Washington, D.C. 20001, beginning on August 6, 2021, at 9:00 a.m. (Eastern) or at a time and
`
`place to be agreed upon by the parties and continuing from day to day, excluding weekends, until
`
`completed. The deposition shall be upon oral examination before an officer appointed or
`
`designated under Federal Rule of Civil Procedure 28, and shall be recorded by audio-visual and
`
`stenographic means.
`
`
`
`
`
`
`
`
`
`
`
`1
`
`
`
`
`
`Case 1:20-cv-00393-LO-TCB Document 721-4 Filed 06/16/21 Page 3 of 9 PageID# 17752
`
`
`Dated: June 11, 2021
`
`Respectfully submitted,
`
`Stephanie E. Parker
`JONES DAY
`1221 Peachtree Street, N.E.
`Suite 400
`Atlanta, GA 30361
`Telephone: (404) 521-3939
`Facsimile: (404) 581-8330
`Email: separker@jonesday.com
`
`Anthony M. Insogna
`JONES DAY
`4655 Executive Drive
`Suite 1500
`San Diego, CA 92121
`Telephone: (858) 314-1200
`Facsimile: (844) 345-3178
`Email: aminsogna@jonesday.com
`
`William E. Devitt
`JONES DAY
`77 West Wacker
`Suite 3500
`Chicago, IL 60601
`Telephone: (312) 269-4240
`Facsimile: (312) 782-8585
`Email: wdevitt@jonesday.com
`
`Sanjiv P. Laud
`JONES DAY
`90 South Seventh Street
`Suite 4950
`Minneapolis, MN 55402
`Telephone: (612) 217-8800
`Facsimile: (844) 345-3178
`Email: slaud@jonesday.com
`
`
`
`
`
`
`
`
`
`
`/s/ David M. Maiorana
`David M. Maiorana (VA Bar No. 42334)
`Ryan B. McCrum
`JONES DAY
`901 Lakeside Avenue
`Cleveland, OH 44114
`Telephone: (216) 586-3939
`Facsimile: (216) 579-0212
`Email: dmaiorana@jonesday.com
`Email: rbmccrum@jonesday.com
`
`John J. Normile
`JONES DAY
`250 Vesey Street
`New York, NY 10281
`Tel: (212) 326-3939
`Fax: (212) 755-7306
`Email: jjnormile@jonesday.com
`
`Alexis A. Smith
`JONES DAY
`555 South Flower Street
`Fiftieth Floor
`Los Angeles, CA 90071
`Telephone: (213) 243-2653
`Facsimile: (213) 243-2539
`Email: asmith@jonesday.com
`
`Charles B. Molster, III (VA Bar No. 23613)
`The Law Offices of Charles B. Molster III PLLC
`2141 Wisconsin Ave., N.W., Suite M
`Washington, DC 20007
`Telephone: (703) 346-1505
`Email: cmolster@molsterlaw.com
`
`Counsel for Plaintiffs RAI Strategic Holdings, Inc.
`and R.J. Reynolds Vapor Company
`
`
`
`
`
`
`
`
`
`
`
`2
`
`
`
`Case 1:20-cv-00393-LO-TCB Document 721-4 Filed 06/16/21 Page 4 of 9 PageID# 17753
`
`
`CERTIFICATE OF SERVICE
`
`
`
`I hereby certify that on June 11, 2021, the foregoing was served on counsel for Defendants
`
`using the following designated email address: pmiedva.lwteam@lw.com.
`
`
`
`Dated: June 11, 2021
`
`
`
`
`
`
`
`
`
`
`/s/ David M Maiorana
`David M. Maiorana (VA Bar No. 42334)
`JONES DAY
`901 Lakeside Avenue
`Cleveland, OH 44114
`Telephone: (216) 586-3939
`Facsimile: (216) 579-0212
`Email: dmaiorana@jonesday.com
`
`
`
`
`3
`
`
`
`Case 1:20-cv-00393-LO-TCB Document 721-4 Filed 06/16/21 Page 5 of 9 PageID# 17754
`
`
`SCHEDULE A TO PLAINTIFF R.J. REYNOLDS VAPOR COMPANY’S THIRD
`NOTICE OF RULE 30(B)(6) DEPOSITION TO DEFENDANT PHILIP MORRIS
`PRODUCTS S.A.
`DEFINITIONS
`
`1.
`
`“ACS” shall each mean and refer to Altria Client Services LLC, including without
`
`limitation all of its corporate locations, and all predecessors, predecessors-in-interest, and all past
`
`or present directors, officers, agents, representatives, employees, consultants, attorneys, entities
`
`acting in joint venture, licensing agreements, or partnership relationships with ACS, and others
`
`acting on behalf of ACS.
`
`2.
`
`“Compatible Tobacco Stick” or “Compatible Tobacco Sticks” means all
`
`compatible tobacco sticks, and each version thereof, for use with any version of the IQOS® System,
`
`including but not limited to, IQOS® HEETS, MarlboroTM HeatSticks, MarlboroTM Fresh Menthol
`
`HeatSticks, or MarlboroTM Smooth Menthol HeatSticks. This definition shall further include any
`
`smaller breakdown of parts, if applicable, for all Compatible Tobacco Sticks.
`
`3.
`
`“IQOS® System” or “IQOS® Systems” means the IQOS® electric tobacco heating
`
`device systems, including the holder, charger, and each version thereof. This definition shall
`
`further include any smaller breakdown of parts, if applicable, for the IQOS® System.
`
`4.
`
`“IQOS® Product” or “IQOS® Products” means the IQOS® System and Compatible
`
`Tobacco Sticks, including all versions thereof. This definition shall further include any smaller
`
`breakdown of parts, if applicable, for all IQOS® Products.
`
`5.
`
`“PM USA” shall mean and refer to Philip Morris USA, Inc., including without
`
`limitation all of its corporate locations, and all past or present directors, officers, agents,
`
`representatives, employees, consultants, attorneys, entities acting in joint venture, licensing
`
`agreements, or partnership relationships with PM USA, and others acting on behalf of PM USA.
`
`
`
`4
`
`
`
`Case 1:20-cv-00393-LO-TCB Document 721-4 Filed 06/16/21 Page 6 of 9 PageID# 17755
`
`
`6.
`
`“PMP” shall mean and refer to Philip Morris Products S.A., including without
`
`limitation all of its corporate locations, and all past or present directors, officers, agents,
`
`representatives, employees, consultants, attorneys, entities acting in joint venture, licensing
`
`agreements, or partnership relationships with PMP, and others acting on behalf of PMP.
`
`7.
`
`“Product” or “Products” shall mean a machine, manufacture, apparatus, device,
`
`instrument, mechanism, appliance, composition of matter, assemblage of components/parts (either
`
`individually or collectively), process, or method which are designed to function together
`
`electrically, mechanically, chemically, or otherwise, to achieve a particular function or purpose,
`
`including those offered for sale, sold, or under development.
`
`8.
`
`“Relate to,” “Related to,” “Relating to,” or “Concerning” shall mean in any way
`
`concerning, constituting, comprising, containing, setting forth, summarizing, reflecting, stating,
`
`describing, recording, noting, embodying, mentioning, studying, analyzing, evaluating,
`
`discussing, contemplating, or referencing a specified subject either directly or indirectly.
`
`9.
`
`10.
`
`11.
`
`12.
`
`“The ’265 patent” means United States Patent No. 9,814,265.
`
`“The ’556 patent” means United States Patent No. 10,555,556.
`
`“The ’911 patent” means United States Patent No. 10,104,911.
`
`“VEEV E-Cigarette Product ” or “VEEV E-Cigarette Products” shall mean the e-
`
`vapor product platform made by or on behalf of PMP (as described further at
`
`https://www.pmi.com/smoke-free-products/veev-innovating-e-vapor-technology).
`
`INSTRUCTIONS
`
`1.
`
`In construing the deposition topics, the singular form of a word should be
`
`interpreted in the plural as well. Any pronoun shall be construed to refer to the masculine,
`
`feminine, or neutral gender as in each case is most appropriate. The words “and” and “or” shall
`
`
`
`5
`
`
`
`Case 1:20-cv-00393-LO-TCB Document 721-4 Filed 06/16/21 Page 7 of 9 PageID# 17756
`
`
`be construed conjunctively or disjunctively, whichever makes the request most inclusive. The
`
`word “including” shall be without limitation. The terms “each” and “any” shall mean any and all.
`
`2.
`
`Connective terms such as “and” or “or” shall be construed either disjunctively or
`
`conjunctively, as necessary, to bring within the scope of the topic all information which might
`
`otherwise be construed to be outside of its scope.
`
`3.
`
`PMP should respond to each Deposition Topic based upon PMP’s entire knowledge
`
`concerning that Topic, from all sources and all information in PMP’s possession or otherwise
`
`available to PMP, including information from current and former officers, employees, agents,
`
`representatives, consultants, or attorneys and information which is known to each of them.
`
`TOPIC NO. 84:
`
`
`
`DEPOSITION TOPICS
`
`
`
`PMP’s plans to market and sell the VEEV E-Cigarette Product in the United States,
`
`including but not limited to any business plans or strategic plans for the regulatory approval,
`
`marketing, sale, and commercialization of the VEEV E-Cigarette Product in the United States.
`
`TOPIC NO. 85:
`
`
`
`
`
`Any PMTA application or potential PMTA application related to the VEEV E-Cigarette
`
`Product, including the current status of any such application and the current plans and timeline for
`
`submission of any such application.
`
`TOPIC NO. 86:
`
`
`
`
`
`Forecasts and projections of sales of the VEEV E-Cigarette Product in the United States,
`
`and any studies or analysis of how the VEEV E-Cigarette Product is expected to perform in the
`
`United States.
`
`
`
`6
`
`
`
`Case 1:20-cv-00393-LO-TCB Document 721-4 Filed 06/16/21 Page 8 of 9 PageID# 17757
`
`
`TOPIC NO. 87:
`
`
`
`
`
`The expected market competition, and any competitive analyses related to such
`
`competition, between VEEV E-Cigarette Products and other e-vapor or vaping Products in the
`
`United States, between VEEV E-Cigarette Products and IQOS® Products in the United States, and
`
`between VEEV E-Cigarette Products and other potentially reduced risk products in the United
`
`States.
`
`TOPIC NO. 88:
`
`
`
`
`
`Marketing and advertising strategies and plans for the VEEV E-Cigarette Product in the
`
`United States, and any planned advertisements or promotional materials for the VEEV e-cigarette
`
`Product in the United States.
`
`TOPIC NO. 89:
`
`
`
`
`
`Any studies, testing, or scientific evidence that PMP intends to use in support of any PMTA
`
`application for the VEEV E-Cigarette Product.
`
`TOPIC NO. 90:
`
`
`
`
`
`Any analysis of the impact on public health from VEEV E-Cigarette Products.
`
`TOPIC NO. 91:
`
`
`
`
`
`Any studies or analyses related to dual use of the VEEV E-Cigarette Products, and any
`
`studies or analyses related to youth use or the potential for youth use of VEEV E-Cigarette
`
`Products.
`
`TOPIC NO. 92:
`
`
`
`
`
`The status and details of any agreements or potential agreements, or the negotiation of any
`
`such agreements or potential agreements, between PMP and any other entity concerning the
`
`importation, distribution, marketing, or sale of VEEV E-Cigarette Products in the United States.
`
`
`
`7
`
`
`
`Case 1:20-cv-00393-LO-TCB Document 721-4 Filed 06/16/21 Page 9 of 9 PageID# 17758
`
`
`TOPIC NO. 93:
`
`
`
`
`
`The factual basis for PMP’s contention that RJRV’s alleged infringement of the ’265, ’911,
`
`and ’556 Patents will cause irreparable harm related to the VEEV E-Cigarette Product, including
`
`but not limited to PMP’s contention that “Reynolds’ infringement . . . has harmed VEEV’s future
`
`standing in the U.S. market” and that “VEEV’s trajectory in the United States already has been
`
`negatively affected by Reynolds’ infringement.”
`
`
`
`8
`
`